MoneyWorks4Me

Sanjivani Paranteral - Quaterly Results

28 Oct 2024 Evaluate
The sales surged to Rs. 181.31 millions, up 29.48% for the September 2024 quarter as against Rs. 140.03 millions during the corresponding quarter previous year.Net Profit recorded in the quarter ended September 2024 rise to 34.58% to Rs. 22.96  millions  compared to R. 17.06 millions in corresponding previous quarter.Operating profit for the quarter ended September 2024 rose to 32.42 millions as compared to 22.64 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 181.31 140.03 29.48 345.68 265.84 30.03 544.10 354.92 53.30
Other Income 3.89 1.50 159.33 4.75 2.10 126.19 5.17 5.54 -6.68
PBIDT 32.42 22.64 43.20 56.65 43.35 30.68 87.58 61.90 41.49
Interest 1.80 0.46 291.30 1.96 0.89 120.22 2.54 3.59 -29.25
PBDT 30.62 22.18 38.05 54.69 42.46 28.80 85.04 58.31 45.84
Depreciation 1.46 2.32 -37.07 2.79 4.61 -39.48 9.33 8.88 5.07
PBT 29.16 19.86 46.83 51.90 37.85 37.12 75.71 49.43 53.17
TAX 6.20 2.80 121.43 11.80 5.30 122.64 14.07 4.34 224.19
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.48 -6.10 -107.87
PAT 22.96 17.06 34.58 40.10 32.55 23.20 61.64 45.09 36.70
Equity 116.84 99.98 16.86 116.84 99.98 16.86 116.84 99.98 16.86
PBIDTM(%) 17.88 16.17 10.60 16.39 16.31 0.50 16.10 17.44 -7.71
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..